Pharma was unable to punt all the drug pricing blame to pharmacy benefits managers at the 10 May Senate HELP hearing on affordable insulin, though the PBM-focused fury was more bipartisan.
Democratic Senators pushed pharma companies beyond insulin pricing during a 10 May Health, Education, Labor and Pensions Committee hearing that was technically focused on the diabetes drug, offering manufacturers a crucial lesson in concession making: sometimes they get you out of the crosshairs, and sometimes they get you more requests for concessions.
The hearing, held the day before the HELP committee will return to marking up four bipartisan drug pricing bills that...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
